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Epigenetic mutations have a great relevance in early stages of HNSCC
Epimutations can be used to develop HNSCC early diagnosis protocols
All data compiled during this bachelor thesis is publicly available in the following web: 
www.epineck.weebly.com
Conclusions
Gene silencing pattern follows a rational sequence based on their molecular biology.
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 Does gene silencing follow a rational pattern?
Fig.5: Does gene silencing follow a rational pattern?: From left to right HPV+, HPV- and ECS. The upper side of this image sequence represents column 
diagrams where the classication is shown by tumour type. The lower side shows thre cells and the rational pattern the gene silencing follows.
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Epineck: HNSCC silenced gene database and browser
Fig.6:  Epineck:  HNSCC  silenced gene database &  browser. A: Epineck webpage  has  been  created “www.epineck.weebly.com” where database and
browser document and project information is available. B: When download button is clicked, a Excel datasheet download starts, this excel datasheet 
contains  both  browser  and  database.   C :  An image  of  the database with  its dierent  columns. D :  Search can  be  done  by  introducing  several
keywords in the  browser, these keywords are written on the right part of the image. D: Results appear in “Results”  page with all the genes that fulll 
your query.
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Methylation array objectives
Epineck methylation array objectives and gene classication: From left to right. The main objective of this array is to allow early stage 
diagnosis of HNSCC. In order to accomplish this goal, array genes have been classied into HNSCC diagnosis, HPV positive  or negative and
extracapsullar spread (ECS).  Candidate genes have been functionally classied and this has been  represented in a column diagram.
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In  the  upper side  results obtained  from the  array are  presented, where
three  dierent genes are  presented(A: non-methylated, B: not signicant
and C methylated).  In  the lower  side, an hypothetical   presentation  of  
matrix clustering of dierent  patients classied by tumour type.
MeDIP (Methylated DNA ImmunoPrecipitation)-chip technique:  This gure shows the protocol for HNSCC diagnosis by using MeDIP-chip from the tumour extraction to the computational analysis. 
A key point in the immunoprecipitation is the election of anti-5mc antibody. It has to be previously tested as it is not sold for diagnostic
use.  Hybridization is done with the   personalized array created based on candidate genes of  Epineck database  following specications  
in the kit.
Sample obtention can be done by brushing or 
by   tumour   extirpation,   depending  on  the
characteristics of the tumour.
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HNSCC development and diagnosis strategy: HNSCC development is inversely related to survival rate, at rst stage CDKN2A, TP53 and MLH1 are silenced, later these silenced gene turns into mutations in 
oncogenes that start neoplasic process which can spread around the body at the last stage.
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5-years prognosis depending on detection stage
5-years prognosis depending on detection stage, mortality rate is sketched as 
ten people, where alive is represented as orange person and death as black o
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Incidence and mortality rates of HNSCC: ASR represent number of sick people per 100,000 
healthy people in a age-standardize population. 
Diagnosis and death statistics, outty pie piece represent the percentage of HNSCC in 
comparison to the whole cancer population. 
700,000 people
diagnosed with 
HNSCC each year
(*6,5% of total cases)
375,000 deaths
 caused by 
HNSCC each year 
(*7% of total cases)
*
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HNSCC diagnostic methylation array: Objectives and discussion
Roadmap to epigenetic diagnosis: From patient’s mouth to bedside
HNSCC developement and diagnosis strategy
HNSCC general facts and statistics
